The service is set to launch in Q2 2025, with a continuously expanding portfolio.

The PCR-based technology developed and patented by MRC Holland is considered the gold standard for accurately determining genetic copy number variations. Due to its versatility, this method can also be applied to detect DNA methylation alterations associated with the development of neoplastic and hereditary genetic diseases, as well as quantitative variations ranging from small gene segments to entire chromosomes.

At our laboratory, we analyze diagnostically and clinically significant markers in cancer, including prognostic markers that help predict disease progression and therapeutic responses.

For more details about our testing portfolio, please feel free to contact us.

Email: seq.acf@med.u-szeged.hu